m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0167)
Name
Lupus erythematosus
ICD
ICD-11: 4A40
Full List of Target Gene(s) of This m6A-centered Disease Response
Mammalian target of rapamycin complex 2 (mTORC2)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary Functionally, the overexpression of ALKBH5 promoted apoptosis and inhibited the proliferation of T cells. ALKBH5 expression is downregulated in systemic lupus erythematosus (SLE) patients and could affect the apoptosis and proliferation of T cells.
Responsed Disease Lupus erythematosus [ICD-11: 4A40]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
TNF alpha-induced protein 3 (TNFAIP3)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [2]
Response Summary miR-19a regulated TNF alpha-induced protein 3 (TNFAIP3) degradation by downregulating the expression of YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2). The circGARS sponges miR-19a to regulate YTHDF2 expression to promote SLE progression through the A20/NF-Kappa-B axis and acts as an independent biomarker to help the treatment of SLE patients.
Responsed Disease Lupus erythematosus [ICD-11: 4A40]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Up regulation
Cell Process Immunity
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
References
Ref 1 Down-regulated ALKBH5 Expression Could Affect the Function of T Cells in Systemic Lupus Erythematosus Patients. Curr Pharm Des. 2022 Jun 17. doi: 10.2174/1381612828666220617154204. Online ahead of print.
Ref 2 N6-methyladenosine-dependent modification of circGARS acts as a new player that promotes SLE progression through the NF-KappaB/A20 axis. Arthritis Res Ther. 2022 Feb 4;24(1):37. doi: 10.1186/s13075-022-02732-x.